How to buy Oracle (ORCL) stock from India

Yes, an Indian resident can buy Oracle — legally, in US dollars, under the RBI's Liberalised Remittance Scheme (LRS). The buying is the easy 10%. The 90% that decides your outcome is dividend withholding, capital-gains tax, estate-tax exposure, and position sizing in a name that has been re-rated on the AI-cloud thesis. This is the short version.

The 30-second version

• Legal and simple. Buy ORCL via any India-facing platform (Vested, INDmoney) or a global broker (Interactive Brokers, Rovia). Whole shares or a fractional rupee amount.
• Dividend + capital gains. Oracle pays roughly a 1% dividend (a $0.50 quarterly payout, regularly grown), so the 25% US dividend withholding does matter — and is creditable in India via Form 67.
• India tax on gains: more than 24 months → 12.5% LTCG (no indexation); sooner → your slab rate. Section 112, not the friendlier 112A that Indian shares get.
• The trap most miss: directly-held ORCL is a US-situs asset — above $60,000, your estate faces up to 40% US estate tax, with no India-US treaty relief.
• If your thesis is "US tech," VOO and VTI already hold ORCL — at a smaller weight than the hyperscaler trio of Microsoft, Amazon, and Google.

Quick facts

Can an Indian resident buy it?	Yes — fully legal under the LRS
Ticker / exchange	ORCL / NYSE
How	India-facing platform (Vested, INDmoney) or global broker (IBKR, Rovia)
Minimum	A fraction of one share
Dividend	~1% yield; $0.50 quarterly, regularly raised
US dividend WHT	25% at source; creditable via Form 67
India tax on gains	12.5% LTCG after 24 months; else slab (Section 112)
Estate-tax risk	US-situs above $60k → up to 40%, no treaty relief
Annual compliance	Schedule FA disclosure, every year you hold

How to buy it — 3 steps

1. Open an account + finish KYC. Pick an India-facing platform (Vested, INDmoney) for a simple, India-funded experience, or a global broker (Interactive Brokers, Rovia) for wider access. New to this? Start with how to invest in US stocks from India.
2. Fund it via the LRS. Remit from your Indian bank under the LRS (cap: $250,000 per financial year). 20% TCS above ₹10 lakh in a year is a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator.
3. Place the order. ORCL trades on the NYSE in regular US market hours. A whole share is affordable on most platforms, or buy a fractional rupee amount.

The tax that actually matters

Oracle is one of the rare US tech names that pays a real (if modest) dividend, so the tax story has two layers.

Dividends. The US withholds 25% at source. The gross dividend is then taxable in India at your slab rate, but you can claim a foreign tax credit for the 25% by filing Form 67 before your ITR. Walkthrough: dividend withholding and Form 67 and the Form 67 / FTC calculator.

Capital gains. Taxed under Section 112 (foreign shares don't get the Section 112A treatment Indian-listed equity enjoys):

Holding period	Treatment	Rate
24 months or less	Short-term	Your slab rate (up to ~30%+)
More than 24 months	Long-term	12.5%, no indexation

Worked example. Buy 20 shares at $190 when USD/INR is 86 → cost ₹3,26,800. Sell 30 months later at $240 when USD/INR is 88 → proceeds ₹4,22,400. Taxable gain ₹95,600; LTCG at 12.5% = ₹11,950. The gain is computed in rupees, so the currency move is baked in. Model your own with the US capital-gains calculator; full rules in how US stocks are taxed in India.

The $60,000 estate-tax trap

Directly-held ORCL is a US-situs asset. If the holder dies with more than $60,000 of US-situs assets, the estate faces US estate tax up to 40% — and the India-US treaty does not cover estate tax, so there's no credit or relief. It's the most under-appreciated risk in direct US holding, and the fix (pooled or fund structures instead of direct shares) has to be a deliberate choice made before the position gets large. Full detail: the $60,000 estate-tax trap.

Buy the stock, or get Oracle through an ETF?

If you want…	Best route
A concentrated bet that OCI keeps outgrowing the hyperscalers	ORCL directly
"US tech / AI-cloud will keep winning" exposure	VOO or VTI — ORCL is in there, plus hundreds of others
The least single-stock risk	A broad ETF

ORCL is in VOO and VTI, at a smaller weight than the hyperscaler trio of Microsoft, Amazon, and Google — so an S&P 500 fund gives you Oracle plus the rest of the AI-infrastructure stack in one wrapper. Compare in direct stocks vs US ETFs and best US ETFs for Indian investors; the broader case is in US ETFs for Indians.

The business in one screen

What it is: Oracle is the world's largest enterprise database vendor and, more recently, the fastest-growing of the major cloud providers. OCI has scaled from fourth-place curiosity to a serious AI-training platform, anchored by huge multi-year contracts and a remaining-performance-obligations backlog that has crossed half a trillion dollars.

Bull case	Bear case
OCI growing fastest of the big clouds off a smaller base	Massive AI-capex straining the balance sheet
Huge AI-infra contracts (OpenAI/Stargate, TikTok, xAI, Meta, Nvidia)	Valuation re-rated dramatically — priced for perfection
Multi-cloud links with Azure, AWS, GCP open enterprise migration	Execution risk on converting a backlog this size
Database franchise durable and cash-generative	Legacy database growth slow; key-customer concentration

Exact valuation is in the live widget above — a genuinely transformed business priced for that transformation to keep delivering.

Our take

Verdict: HOLD — credible AI-cloud second-act, but a re-rated multiple and AI-capex-funded balance sheet leave less margin for error than the share price suggests.

• The bull side is real. OCI's growth leads the hyperscalers, the multi-year backlog is enormous, and the database moat keeps funding the cloud build-out.
• The risks are equally real. Capex is running at hyperscaler scale on a smaller revenue base, the backlog is concentrated in a handful of mega-customers, and the valuation already prices in successful conversion for years.
• Position sizing matters more than entry timing. Treat ORCL as a satellite alongside broad US-tech exposure, not a core compounder — single-customer renegotiations or capex slippage can move this stock hard.

Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.

Risks to size for

• Valuation re-rating: priced on the AI thesis; any wobble in OCI growth or capex discipline can compress the multiple fast.
• Customer concentration: a small set of frontier-AI buyers underpin a very large slice of the backlog.
• Currency: your return is in USD but you spend rupees — see the rupee-dollar effect.

Two things people forget

• Schedule FA: disclose ORCL — and its dividends — in Schedule FA of your ITR every year you hold it, even if bought and sold within the year, even at a loss. Non-disclosure carries Black Money Act penalties. Use the Schedule FA helper.
• Claim the dividend credit: the 25% US withholding is creditable, not lost — but only if you file Form 67 before your ITR. Skip it and you effectively pay tax twice on the same dividend.

Bottom line

Buying ORCL from India is easy and legal. What needs thought isn't the buying — it's that Oracle is a Section-112 capital-gains play (12.5% after 24 months), a dividend payer with 25% US withholding to reclaim via Form 67, a US-situs asset with a $60k estate-tax trap, and a name priced for its AI-cloud second act to keep compounding. If your real thesis is "US tech and AI infrastructure," a broad ETF gives you Oracle plus everyone competing for the same workloads. For accounts and options, start at the US investing hub.

---

This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.